

# Biochemical Actions of Hormones

Edited by GERALD LITWACK

VOLUME X

# Biochemical Actions of Hormones

Edited by GERALD LITWACK

*Fels Research Institute and Department of Biochemistry  
Temple University, School of Medicine  
Philadelphia, Pennsylvania*

VOLUME X

1983



ACADEMIC PRESS

A Subsidiary of Harcourt Brace Jovanovich, Publishers

New York London

Paris San Diego San Francisco São Paulo Sydney Tokyo Toronto

COPYRIGHT © 1983, BY ACADEMIC PRESS, INC.

ALL RIGHTS RESERVED.

NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT PERMISSION IN WRITING FROM THE PUBLISHER.

ACADEMIC PRESS, INC.

111 Fifth Avenue, New York, New York 10003

*United Kingdom Edition published by*  
ACADEMIC PRESS, INC. (LONDON) LTD.  
24/28 Oval Road, London NW1 7DX

Library of Congress Cataloging in Publication Data  
Main entry under title:

Biochemical actions of hormones.

Includes bibliographies.

1. Hormones--Collected works. I. Litwack, Gerald, ed.

II. Axelrod, Julius, Date. [DNLM: 1. Hormones.

2. Physiology. WK102 B615]

QP571.B56 574.19'27 70-107567

ISBN 0-12-452810-4 (v. 10)

PRINTED IN THE UNITED STATES OF AMERICA

83 84 85 86 9 8 7 6 5 4 3 2 1

## Contributors

*Numbers in parentheses indicate the pages on which the author's contributions begin.*

Evelyn R. Barrack (23), The James Buchanan Brady Urological Institute of the Department of Urology, Department of Pharmacology and Experimental Therapeutics, The Johns Hopkins Oncology Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Ralph A. Bradshaw\* (91), Department of Biological Chemistry, Washington University School of Medicine, St. Louis, Missouri 63110

Juan Casanova (115), Division of Molecular Endocrinology, The Rose F. Tishman Laboratories for Geriatric Endocrinology, Department of Medicine, New York University Medical Center, New York, New York 10016

Donald S. Coffey (23), The Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Herbert W. Dickerman (259), Department of Biochemistry, Albany Medical College, Albany, New York 12201

Kevin P. Dolan (1), The Institute of Cancer Research, Department of Biochemistry, College of Physicians and Surgeons, Columbia University, New York, New York 10032

Howard J. Eisen (227), Developmental Pharmacology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20205

\* Present address: Department of Biological Chemistry, University of California—Irvine, California College of Medicine, Irvine, California 92717.

- Philip Feigelson (1), The Institute of Cancer Research, Department of Biochemistry, College of Physicians and Surgeons, Columbia University, New York, New York 10032
- Mark Feldman (303), Department of Surgery and Neoplastic Diseases, Mount Sinai School of Medicine, New York, New York 10029
- David L. Gasser (357), Department of Human Genetics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
- Allen S. Goldman (357), Division of Human Genetics and Teratology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104
- Rita R. Hannah (227), Developmental Pharmacology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20205
- Harriette Haubenstock (383), Department of Neoplastic Diseases, Mount Sinai School of Medicine, New York, New York 10029
- Vincent P. Hollander (303), Department of Surgery and Neoplastic Diseases, Mount Sinai School of Medicine, New York, New York 10029
- Zebulun D. Horowitz (115), Division of Molecular Endocrinology, The Rose F. Tishman Laboratories for Geriatric Endocrinology, Department of Medicine, New York University Medical Center, New York, New York 10016
- Tamiko Kano-Sueoka (163), Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, Colorado 80309
- S. Anand Kumar\* (259), Department of Chemistry, State University of New York at Albany, Albany, New York 12201
- Yannick Laperche (1), The Institute of Cancer Research, Department of Biochemistry, College of Physicians and Surgeons, Columbia University, New York, New York 10032
- Wendell W. Leavitt (323), Worcester Foundation for Experimental Biology, Shrewsbury, Massachusetts 01545

\* Present address: Center for Laboratories and Research, New York State Department of Health, Empire State Plaza, Albany, New York 12201.

Catherine Legraverend (227), Developmental Pharmacology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20205

Kevin R. Lynch (1), The Institute of Cancer Research, Department of Biochemistry, College of Physicians and Surgeons, Columbia University, New York, New York 10032

Richard G. MacDonald (323), Worcester Foundation for Experimental Biology, Shrewsbury, Massachusetts 01545

Margaret McLaughlin (1), The Institute of Cancer Research, Department of Biochemistry, College of Physicians and Surgeons, Columbia University, New York, New York 10032

Hira L. Nakhasi\* (1), The Institute of Cancer Research, Department of Biochemistry, College of Physicians and Surgeons, Columbia University, New York, New York 10032

Daniel W. Nebert (227), Developmental Pharmacology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20205

Allan B. Okey (227), Department of Pediatrics, Division of Clinical Pharmacology, The Hospital for Sick Children, Toronto, Canada M5G 1X8

William C. Okulicz (323), Worcester Foundation for Experimental Biology, Shrewsbury, Massachusetts 01545

Bruce M. Raaka (115), Division of Molecular Endocrinology, The Rose F. Tishman Laboratories for Geriatric Endocrinology, Department of Medicine, New York University Medical Center, New York, New York 10016

Rosemary Reinke (1), The Institute of Cancer Research, Department of Biochemistry, College of Physicians and Surgeons, Columbia University, New York, New York 10032

Herbert H. Samuels (115), Division of Molecular Endocrinology, The Rose F. Tishman Laboratories for Geriatric Endocrinology,

\* Present address: Laboratory of Pathophysiology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205.

Department of Medicine, New York University Medical Center,  
New York, New York 10016

Lawrence E. Shapiro (115), Department of Medicine, Division of  
Endocrinology and Metabolism, Montefiore Medical Center and  
the Albert Einstein College of Medicine, Bronx, New York  
10467

Frederick Stanley (115), Division of Molecular Endocrinology, The  
Rose F. Tishman Laboratories for Geriatric Endocrinology, De-  
partment of Medicine, New York University Medical Center,  
New York, New York 10016

John Stevens (383), Research Department, American Cancer Society,  
New York, New York 10017

Yee-Wan Stevens (383), Memorial Sloan-Kettering Cancer Center,  
New York, New York 10021

Jir S. Tsai (115), Endocrine Division, Department of Medicine, New  
York University Medical Center, New York, New York 10016

Ronald Unterman (1), The Institute of Cancer Research, Department  
of Biochemistry, College of Physicians and Surgeons, Columbia  
University, New York, New York 10032

Albert Volchek (303), Department of Surgery and Neoplastic Diseases,  
Mount Sinai School of Medicine, New York, New York 10029

Franz Waldhauser\* (187), Laboratory of Neuroendocrine Regulation,  
Massachusetts Institute of Technology, Cambridge, Massachusetts  
02139

Richard J. Wurtman (187), Laboratory of Neuroendocrine Regulation,  
Massachusetts Institute of Technology, Cambridge, Massachusetts  
02139

Barry M. Yaffe (115), Division of Molecular Endocrinology, The Rose  
F. Tishman Laboratories for Geriatric Endocrinology, Department  
of Medicine, New York University Medical Center, New York,  
New York 10016

\* Present address: Universitäts-Kinderklinik, Waehringer Guertel 74-76, Vienna A-1090,  
Austria.

## Preface

Two important areas have had impact on biochemical endocrinology recently, one of which is the application of recombinant DNA technology to genes for hormones. New information on the genetic regulation of these genes can be expected. Another exciting development is that the nuclear matrix may represent a preferred acceptor site for certain steroid hormone receptor complexes. These two advances are highlighted in two contributions to this volume, the first as approached by the Feigelson group for the  $\alpha_{2u}$  globulin gene and its regulation by several hormones, and the second by the Coffey laboratory reviewing their observations on the nuclear matrix. An excellent model for determining the roles of various receptors operating at the genetic level has embodied the use of cells in culture derived from the anterior pituitary. These cells are capable of secreting hormones in response to the stimuli of releasing factors as well as other hormones and have retained capacity for feedback inhibition. Progress along these lines is reported in a contribution from the Samuels laboratory. Future volumes can be expected to concentrate on similar models. Since certain polypeptide hormones apparently share ancestral, closely related genes and consequently various aspects of their structures, Bradshaw summarizes this conceptual advance by reviewing the nerve growth factor and related hormones. Also, many of the polypeptide hormones have come to be recognized as growth factors for cells in culture. Kano-Sueoka reviews her work in this area and related studies on factors affecting the growth of mammary cells in culture. Some new insights into the pineal hormone, melatonin, have appeared. These are summarized in a timely article from Wurtman's laboratory.

The remainder of the topics covered here deal with more specific subjects. Recent studies in the Nebert laboratory on the *Ah* receptor have produced a great deal of information on a specific carcinogen receptor which seems to be analogous in many respects to a steroid receptor. This interesting subject appears here for the benefit of endocrinologists who may not be fully aware of this fascinating system. The remaining five chapters center around various aspects of steroid receptors. Current interest has been expressed in specific acceptor sites in genes and their flanking sequences.



Therefore, the work taking place in Dickerman's laboratory on synthetic oligonucleotide acceptors for steroid receptor complexes is reviewed. With this interesting introduction it is to be hoped that future treatises in this series will review the developing work on identifying gene sequences involved in high-affinity binding sites for steroid receptor complexes. Hollander's laboratory reviews mammary tumor growth and response to ovariectomy, which is of particular interest with respect to specific alterations in the estradiol receptor. Leavitt's laboratory reviews the hormonal regulation of estrogen and progesterone receptors. The genesis of cleft palate provides an experimental model which may lead to an understanding of the genetic regulation of factors involved in the expression of activities of the glucocorticoid receptor and possibly to specific chromosomal assignment of these functions. This subject is emphasized in a contribution from Gasser and Goldman. Finally, the Stevens group brings us up to date on the mechanisms of glucocorticoid resistance in leukemia cells and discusses the possibility of two apparently different steroid receptors which could result from the occurrence of separate gene products.

Modern endocrinology is developing very rapidly at the experimental level and is overlapping other disciplines, particularly molecular biology. I will attempt to keep abreast of these developments in future volumes of this publication.

Gerald Litwack

# Contents

Contributors .....	ix
Preface .....	xiii

## 1. The Application of Recombinant Techniques to the Study of the Control of $\alpha_{2u}$ Globulin Gene Expression

*Kevin P. Dolan, Rosemary Reinke, Kevin R. Lynch, Margaret McLaughlin, Ronald Unterman, Hira L. Nakhasi, Yannick Laperche, and Philip Feigelson*

I. Introduction .....	1
II. Cloning .....	3
III. The $\alpha_{2u}$ Globulin Gene .....	10
IV. DNA Methylation .....	16
V. Salivary Gland $\alpha_{2u}$ Globulin Synthesis .....	18
References .....	19

## 2. The Role of the Nuclear Matrix in Steroid Hormone Action

*Evelyn R. Barrack and Donald S. Coffey*

I. Introduction .....	24
II. Isolation and Characterization of the Nuclear Matrix .....	30
III. The Role of the Nuclear Matrix in DNA Replication .....	37
IV. The Association of RNA with the Nuclear Matrix .....	40
V. Regulation of DNA Structure on the Matrix .....	41
VI. The Interaction of Steroid Hormones with the Nuclear Matrix .....	42
VII. Fractionation of the Nuclear Matrix and Localization of Matrix-Associated Steroid Hormone Binding Sites .....	65

VIII. Some Comments on the Nature of Nuclear Matrix-Associated Steroid Binding Sites .....	76
IX. Potential Role of Cellular Structural Components in Hormone Action .....	82
References .....	84

### 3. Nerve Growth Factor and Related Hormones

*Ralph A. Bradshaw*

I. Introduction .....	91
II. The Relationship of Hormones and Growth Factors .....	92
III. Nerve Growth Factor as a Hormone .....	99
IV. Concluding Remarks .....	111
References .....	111

### 4. Hormonal Regulation of Growth Hormone Synthesis in Cell Cultures: Role of Thyroid and Glucocorticoid Hormone Receptors

*Herbert H. Samuels, Juan Casanova, Zebulun D. Horowitz, Bruce M. Raaka, Lawrence E. Shapiro, Frederick Stanley, Jir S. Tsai, and Barry M. Yaffe*

I. Introduction .....	116
II. Cell Culture Considerations .....	117
III. Control of Growth Hormone Synthesis by Thyroid Hormone in Cultured Cells .....	118
IV. Control of Growth Hormone Synthesis by Glucocorticoid Hormones in Cultured Cells .....	136
V. Glucocorticoid Receptors in GH <sub>1</sub> Cells: Physical Characteristics and Nature of the Activation (Transformation) Process .....	146
VI. Concluding Remarks .....	157
References .....	159

### 5. Factors Affecting Mammary Cells in Culture

*Tamiko Kano-Sueoka*

I. Introduction .....	163
II. Methods to Culture Mammary Cells .....	165
III. Mammogenic Hormones as Mitogens .....	166
IV. Growth Factors and Nutrients .....	170
V. Spatial Organization of the Cells and the Cell-Substratum Interaction .....	177
VI. Discussion and Summary .....	181
References .....	183

## 6. The Secretion and Actions of Melatonin

*Franz Waldhauser and Richard J. Wurtman*

I. Introduction .....	187
II. The Mammalian Pineal Organ .....	189
III. Melatonin .....	194
IV. Summary .....	217
References .....	218

## 7. The Ah Receptor: Controlling Factor in the Induction of Drug-Metabolizing Enzymes by Certain Chemical Carcinogens and Other Environmental Pollutants

*Howard J. Eisen, Rita R. Hannah, Catherine Legraverend, Allan B. Okey, and Daniel W. Nebert*

I. Introduction .....	228
II. The Ah-Locus .....	230
III. Characteristics of the Ah Receptor .....	238
IV. Future Directions .....	250
V. Speculation on the Origin and Function of the Ah Receptor .....	252
References .....	254

## 8. Specificity of Nucleic Acid Structure for Binding Steroid Receptors

*S. Anand Kumar and Herbert W. Dickerman*

I. Introduction .....	259
II. Biological Significance of DNA Binding of Steroid Receptors .....	260
III. Separateness of Ligand- and DNA-Binding Domains .....	261
IV. Recognition of DNA Structure by Steroid Receptors .....	270
V. Nucleotide Base Recognition of Steroid Receptors .....	272
VI. Potential Modulators of Steroid Holoreceptor:DNA Interaction .....	287
VII. An Allosteric Model of Steroid Receptor:DNA Interaction .....	294
References .....	297

## 9. Mammary Tumor Growth and Response to Ovariectomy

*Mark Feldman, Albert Volchek,  
and Vincent P. Hollander*

I. Introduction .....	303
II. Early Studies .....	304
III. Estradiol Receptor as an Index of Hormonal Responsiveness .....	305
IV. MTW9 Rat Mammary Tumor Model .....	306
V. Growth Factors for Mammary Tumor Cells .....	313

VI. Summary .....	319
References .....	319
 10. Hormonal Regulation of Estrogen and Progesterone Receptor Systems	
<i>Wendell W. Leavitt, Richard G. MacDonald, and William C. Okulicz</i>	
I. Introduction .....	324
II. Methods .....	326
III. Serum Steroid-Uterine Receptor Relationships .....	329
IV. Progesterone Regulation of Nuclear Estrogen Receptor during the Estrous Cycle .....	333
V. Estrogen Receptor Recovery in the Progesterone-Dominated Uterus .....	344
VI. Summary and Conclusions .....	348
References .....	354
 11. Genetic and Biochemical Studies on Glucocorticoid-Induced Cleft Palate	
<i>David L. Gasser and Allen S. Goldman</i>	
I. Introduction .....	357
II. Normal Secondary Palatal Development .....	358
III. Effect of Glucocorticoids .....	360
IV. Genetics of the H-2 and H-3 Regions .....	364
V. Biochemical Effects of Glucocorticoids .....	369
VI. Glucocorticoids, Shelf Elevation, and Programmed Cell Death .....	374
VII. Genetics of Clefting in Humans .....	376
VIII. Summary .....	376
References .....	377
 12. Molecular Basis of Glucocorticoid Resistance in Experimental and Human Leukemia	
<i>John Stevens, Yee-Wan Stevens, and Harriette Haubenstock</i>	
I. Introduction .....	384
II. Glucocorticoid Effects on Corticoid-Sensitive Lymphocytes .....	384
III. Resistance to Glucocorticoids in Animal Model Systems .....	386
IV. Resistance to Glucocorticoids in Human Leukemia and Lymphoma .....	433
V. Conclusions .....	440
References .....	441
Index .....	447
Contents of Previous Volumes .....	463

## CHAPTER 1

# The Application of Recombinant Techniques to the Study of the Control of $\alpha_{2u}$ Globulin Gene Expression

*Kevin P. Dolan, Rosemary Reinke,  
Kevin R. Lynch, Margaret McLaughlin,  
Ronald Unterman, Hira L. Nakhasi,  
Yannick Laperche, and Philip Feigelson*

I. Introduction .....	1
II. Cloning .....	3
III. The $\alpha_{2u}$ Globulin Gene .....	10
IV. DNA Methylation .....	16
V. Salivary Gland $\alpha_{2u}$ Globulin Synthesis .....	18
References .....	19

### I. INTRODUCTION

$\alpha_{2u}$  Globulin is a small ( $M_r$  18,700,  $pI$  5.1–5.5) protein synthesized predominantly in the liver and excreted in the urine of male rats (Roy and Neuhaus, 1966a; Roy *et al.*, 1966). It was first described by Roy *et al.*, who found it in the urine of male but not female rats and demonstrated that in order to excrete normal levels of  $\alpha_{2u}$  globulin an adult male rat requires androgen, glucocorticoid, growth hormone, thyroxine, and insulin

(Roy and Neuhaus, 1967; Roy, 1973a,b; Roy and Leonard, 1973). Female rats will excrete  $\alpha_{2u}$  globulin in response to androgen only if they are first ovariectomized (Sippel *et al.*, 1975);  $\alpha_{2u}$  globulin excretion is drastically reduced in male animals by estrogen treatment (Roy *et al.*, 1975).

Glucocorticoids have been shown to act directly on hepatocyte suspensions *in vitro* to elevate  $\alpha_{2u}$  globulin synthesis and secretion and this induction was shown to be  $\alpha$ -amanitin sensitive (Chen and Feigelson, 1978, 1980). It should be noted, however, that the stimulatory effects of androgen, thyroid hormone, growth hormone, and insulin, as well as the suppressive effect of estrogen, have only been convincingly demonstrated *in vivo*. The possibility exists that certain of these latter hormones may elicit their hepatic  $\alpha_{2u}$  globulin responses indirectly, e.g., estrogen via prolactin, thyroid hormone via growth hormone, and insulin and growth hormone via somatomedin. Thus,  $\alpha_{2u}$  globulin synthesizing hepatocytes might be directly responding to a smaller set of hormones.

In addition to the complex hormonal control of  $\alpha_{2u}$  globulin synthesis in adult male rats, its synthesis also follows a distinct developmental pattern.  $\alpha_{2u}$  globulin is undetectable in the urine of male rats until the onset of puberty (about 31 days of age) (Roy, 1973b). From this point until adulthood the amount of  $\alpha_{2u}$  globulin excreted increases reaching the mature level of approximately 20 mg/day at about 50 days of age.  $\alpha_{2u}$  Globulin is excreted in this quantity throughout the life of the adult male rat, decreasing again to nearly undetectable levels in senescence (Roy and Neuhaus, 1966b; Roy *et al.*, 1974). Prior to the onset of puberty, administration of androgen will not induce  $\alpha_{2u}$  globulin excretion (Roy, 1973b). Rats castrated before puberty, however, respond to androgen administration after 50 days of age by excreting  $\alpha_{2u}$  globulin at near normal levels. It therefore appears that androgen is not required for the development of the competence to synthesize this protein. Conversely, hypophysectomy does prevent the development of this competence. Male rats hypophysectomized after puberty respond to injections of androgen, growth hormone, glucocorticoid, and thyroxine by excreting approximately normal levels of  $\alpha_{2u}$  globulin, while animals hypophysectomized before puberty and treated similarly with these hormones at 65 days of age excrete only about 10% the normal levels (Lynch *et al.*, 1982) (Fig. 1). These results suggest that a hormone provided or directed by the pituitary is responsible for the development of the competence of the mature male liver to respond normally to androgen.

Further interest in the control of  $\alpha_{2u}$  globulin synthesis is based on the finding that several transplantable hepatomas have lost the ability to synthesize this protein although the livers of the host rats continue to do so normally (Sippel *et al.*, 1976; Feigelson and DeLap, 1977). Thus, it is evident that understanding the control of  $\alpha_{2u}$  globulin synthesis has the

potential to provide useful insights into basic biological questions including the mechanisms responsible for tissue specific differentiation, the mode of actions of polypeptide, steroid, and other hormones, and the basis for altered gene expression consequent to neoplastic transformation. Considerable effort has, therefore, been focused on the elucidation of the biochemical processes underlying this complex hormonal and developmental control.

In order to determine whether the altered rates of  $\alpha_{2u}$  globulin synthesis were due to fluctuations in the level of its mRNA, the hepatic levels of functional  $\alpha_{2u}$  globulin mRNA were measured. These experiments involved the translation, in a heterologous cell-free system, of the mRNA isolated from the livers or tumors of rats in different hormonal states. The  $\alpha_{2u}$  globulin synthesized *in vitro* under the direction of this mRNA was precipitated with monospecific antibody to  $\alpha_{2u}$  globulin, separated on sodium dodecyl sulfate (SDS)-polyacrylamide gels, and quantified. In every case of endocrine (Kurtz *et al.*, 1976a,b; Roy and Dowbenko, 1977; Lynch *et al.*, 1982; Roy, 1973a,b; Roy and Leonard, 1973; Roy *et al.*, 1976a,b; Feigelson and Kurtz, 1978; Chen and Feigelson, 1980), developmental (Chatterjee and Roy, 1980), and neoplastic control (Sippel *et al.*, 1976; Feigelson and DeLap, 1977; Nakhasi *et al.*, 1982), the enrichment of the hepatic mRNA, measured by *in vitro* translation, paralleled exactly its *in vivo* rate of synthesis and the level of  $\alpha_{2u}$  globulin excreted by the animal. A representative experiment of this type is shown in Figs. 1B and 5C. The coordinate rise in  $\alpha_{2u}$  globulin synthesis and in its hepatic mRNA makes it likely that the site of developmental, neoplastic, and endocrine action is prior to the appearance of functional cytoplasmic  $\alpha_{2u}$  globulin mRNA. For reviews of this work see Kurtz and Feigelson (1978) and Roy (1979). While transcription is a likely site of control (Chan *et al.*, 1978), processing of the gene transcript, transport of the mRNA to the cytoplasm, and the stability of each of the processing intermediates are all potential sites of regulation. To distinguish between these alternatives a specific probe capable of hybridizing with  $\alpha_{2u}$  globulin sequences was required.

## II. CLONING

We prepared and cloned  $\alpha_{2u}$  globulin cDNA using standard technology (Unterman *et al.*, 1981). A cDNA copy was made from oligo(dT)-primed mature male liver RNA using reverse transcriptase to synthesize the first strand (Kacian and Myers, 1976) and DNA polymerase I for the second strand (Seeburg *et al.*, 1977). The double-stranded cDNA was inserted in the *Pst*I site of pBR322 by the G-C tailing method and transformed into






FIG. 1. Amount of  $\alpha_{2u}$  globulin RNA present in the livers of hormone-treated hypophysectomized rats. (A) The autoradiograph depicted was generated by electrophoresis of 30  $\mu$ g of total RNA extracted from the livers of prepubescently hypophysectomized (lanes 5, 6, 7, and 8) or postpubescently hypophysectomized (lanes 1, 2, 3, and 4) rats through a 1.75% denaturing agarose gel, after which the RNA was blotted onto nitrocellulose paper and hybridized to  $^{32}$ P-labeled  $\alpha_{2u}$  globulin cDNA. The rats were treated with one of the following hormonal regimens for 12 days: no hormones (lanes 1 and 5); dihydrotestosterone, L-thyroxine, and hydrocortisone